Radiation dosimetry results from a phase II trial of Ibritumomab Tiuxetan (Zevalin™) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

Gregory A. Wiseman*, Thomas E. Witzig, Christine A. White, Bryan R. Leigh, William D. Erwin, Richard B. Sparks, Donald A. Podoloff, Russell J. Schilder, Nancy L. Bartlett, Stewart M. Spies, Antonio J. Grillo-López

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint Dive into the research topics of 'Radiation dosimetry results from a phase II trial of Ibritumomab Tiuxetan (Zevalin™) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia'. Together they form a unique fingerprint.

Medicine & Life Sciences